The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
T. Stinchcombe
Honoraria - Genentech
Research Funding - Genentech
M. A. Socinski
Honoraria - Genentech; Lilly
Research Funding - Celgene; Genentech; Lilly; Pfizer; Synta
D. T. Moore
No relevant relationships to disclose
S. N. Gettinger
No relevant relationships to disclose
R. H. Decker
No relevant relationships to disclose
W. J. Petty
Research Funding - OSI Pharmaceuticals
A. W. Blackstock
No relevant relationships to disclose
G. Schwartz
No relevant relationships to disclose
S. Lankford
No relevant relationships to disclose
D. E. Morris
No relevant relationships to disclose